chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Itchy; Hive-like; Developed a rash on her arm that has now spread to her arms, stomach, legs, and back; Fever; Aches and pain from the vaccine; This spontaneous case was reported by a consumer and describes the occurrence of PAIN (Aches and pain from the vaccine), PRURITUS (Itchy), URTICARIA (Hive-like), RASH (Developed a rash on her arm that has now spread to her arms, stomach, legs, and back) and PYREXIA (Fever) in a 66-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 630A21A and 037K70A or 037K20A) for COVID-19 vaccination.     No Medical History information was reported.   On 11-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 11-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 2 dosage form. On 11-Mar-2021, the patient experienced PAIN (Aches and pain from the vaccine) and PYREXIA (Fever). On 12-Mar-2021, the patient experienced PRURITUS (Itchy), URTICARIA (Hive-like) and RASH (Developed a rash on her arm that has now spread to her arms, stomach, legs, and back). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) ongoing since an unknown date at an unspecified dose and frequency. At the time of the report, PAIN (Aches and pain from the vaccine), PRURITUS (Itchy), URTICARIA (Hive-like), RASH (Developed a rash on her arm that has now spread to her arms, stomach, legs, and back) and PYREXIA (Fever) outcome was unknown.            No concomitant medications reported by reporter. Action taken with mRNA-1273 was not applicable.
My arm started itching at the injection site one week after the first shot.   There was a red, slightly raised, slightly hard spot about 1.5" inches in diameter.  The itching continued for about 4 days.  The redness subsided after 2 days and was a very faint spot..
Several hours after receiving this vaccine (first dose), my right ear began to hurt. The pain intensified as the evening wore on. The next morning the pain was gone, but I had ringing in my ear. In the past I have had some very mild, short-lived bouts of tinnitus before, but this was more intense than I'd ever experienced before. The ringing was loud enough that it broke through daily noise. It was loud enough to break through even during boisterous conversations in a room in which the television set also turned on. It was also so loud that it interfered with my sleep. Over the course of the past several months the ringing in my ears has become softer, but it is still there and still occassionally breaks through the ambient noises of daily life.
2/9/04 Temp 102.8- mom states child became limp and stopped breathing-Mothers grandfather blew air into child's mouth-Emergency medical services called but did not transport-mother and maternal grandparents took child to Peds. seen by doctor for febrile seizure with gastroenteritis- 2/12/04 seen by doctor with dizziness and poor balance-Developed rash 2/13/04 for 3 days.
Very high fever, 103.2 degrees that started 7 hours after the vaccine, severe (piercing) headache and violent chills.  Symptoms lasted for days.  Unable to drive or do much of anything.  My usual body temperature (I have to take and log it daily for work) is 97.5 degrees.  It was the highest fever, most violent chills and most severe headache of my life.
ever since initial dose of vaccine I've had irregular periods that are VERY different from previous cycles. My cycles have been consistent for all I can remember with it being 28-30 day cycles. Ever since the shot my cycles have been 44-50 day cycles. I've told my PCP and they said to wait before reporting. I haven't had a normal period ever since then and am afraid of long term effects of the vaccine towards my reproductive health.
Fell in parking lot after leaving clinic after receiving 1st covid vaccine. Does not appear to be related to the vaccine, but may be related to crappy parking lot.
Initial information received on 19-Oct-2018 regarding an unsolicited non-valid non-serious case received from a consumer/non-health care professional with live follow-up. This case involves Adult female patient (age was not reported) who had swelling and redness, while she received vaccine FLUBLOK QIV. The patient's past medical history, medical treatment(s), vaccination(s), concomitant medication(s) and family history were not provided. On an unknown date, the patient received a dose of suspect INFLUENZA QUADRIVALENT RECOMBINANT VACCINE (lot number, expiry date, dose, dose in series, route and site of administration was not reported). On an unknown date, following the vaccination the patient experienced swelling and redness. (Other relevant tests included no lab data.) Final diagnosis was swelling and redness. It was not reported if the patient received a corrective treatment. The outcome of the events was reported as not recovered. List of documents held by sender: none.
Per patient: Patient received vaccine around noon on the 12 of March 2021 at Community Church. Patient states about 10 -12 hrs later, began an adverse cardiac event. Patient states the day before he injured his knee at work and went to ED from an injury the day before. At the ED they gave Fentanyl and he got sick and told the nurse that he was experience chest pain. Felt burning or falling asleep sensation in arm and chest. Told the nurse he felt like he was having a heart attack. They came in ED with crash cart and confirmed that he was having a heart attack while in ED.  Transported from church to hospital.
Patient states she developed hives to her chest/back with associated edema to the tongue. EMS was on scene and inserted an IV/administered 50 mg of Benadryl. Famotidine 20 mg IV administered in E.D
EXHAUSTION; PAIN IN ARM; SCABBY RASH/RASH ON BACK/UPPER AND LOWER ARM/LEG; ITCHY RED RASH ON BACK/UPPER AND LOWER ARM/LEG; This spontaneous report received from a consumer concerned a 43 year old female. The patient's height, and weight were not reported. The patient's concurrent conditions included asthma, and tiny clot in lung. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, and batch number: 042A21A expiry: UNKNOWN) dose was not reported, administered on 09-APR-2021 for prophylactic vaccination. No concomitant medications were reported.  On APR-2021, the subject experienced itchy red rash on back/upper and lower arm/leg. On APR-2021, the subject experienced scabby rash/rash on back/upper and lower arm/leg. On 09-APR-2021, the subject experienced pain in arm. On 10-APR-2021, the subject experienced exhaustion. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from exhaustion on APR-2021, was recovering from scabby rash/rash on back/upper and lower arm/leg, and the outcome of pain in arm and itchy red rash on back/upper and lower arm/leg was not reported. This report was non-serious.
Fever; Chills; This is a spontaneous report from a contactable consumer, the patient. A 65-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: 02212022) via an unspecified route of administration in the left arm on 29Oct2021 at 09:15 (at the age of 65-years-old) as a single dose for COVID-19 immunisation. The patient had no relevant medical history and no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medication included minocycline (MANUFACTURER UNKNOWN); taken for unknown indication from an unknown date and unknown if ongoing. On 29Oct2021 at 22:00, the patient had fever and chills for about 5 hours. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events fever and chills was resolved on 30Oct2021 at 03:00.
STARTED OUT FEELING SLIGHTLY UNDER THE WEATHER (SATURDAY MORNING) - RUNNY NOSE, BODY ACHES, HEADACHE, ETC.  BEGAN TO COUGH, SNEEZE, GET A STUFFY NOSE, BECOME TIRED THROUGHOUT DAY AND BEGAN TO LOSE SENSE OF TASTE AND SMELL. WENT TO THE LITTLE CLINIC TO GET COVID TEST SAME DAY. HYDRATED AND ATE MINIMALLY DUE TO LOSS OF TASTE AND TIREDNESS. SLEPT AND RESTED APPROX. 15-18 HRS PER DAY UNTIL RESULTS CAME BACK NEGATIVE THE NEXT DAY. CONTINUED TO REST AND HYDRATE AND CONSUME DAYQUIL/NYQUIL UNTIL BODY FELT NORMAL AGAIN.
PATIENT DEVELOPED RASH ALL OVER HER FACE. SHE TOOK SOME BENADRYL BUT THE RASH DID NOT IMPROVE.
Mild 1) one person vaccination, was writing with pen with gloves on after vaccination, then took off gloves, put on new ones, but picked up pen again before vaccination,    patient 2) another person vaccinating - did not gloves off good for a while preparing another patient I reminded him to do so. My suspicion so thus he did not change his gloves before the vaccinations also he   of gloves was on his side of the left only on the Flu other side.
COVID-19; COVID-19; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 71-year-old female patient (not pregnant) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 09May2023 at 12:00 as dose 6 (booster), single (Batch/Lot number: unknown) at the age of 71 years, in left arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown), as dose 3 (booster), single (Batch/Lot number: unknown), as dose 4 (booster), single (Batch/Lot number: unknown) and as dose 5 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "Known allergies: Penicillin" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset May2023, outcome "not recovered" and all described as "COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (May2023) Positive, notes: Treatment of COVID-19; (Jun2023) Positive, notes: Covid rebound. Therapeutic measures were taken as a result of drug ineffective, covid-19.  Clinical course: Pfizer Covid-19 treatment from 24May2023 to 28May2023. Covid rebound on 02Jun2023 at 02:00 PM. The patient had no other medication within 2 weeks.  The information on the batch/lot number for BNT162b2, BNT162b2 omi ba.4-5 has been requested and will be submitted if and when received.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202300211387 same reporter/patient/product, different dose/event.;
Information has been received from a physician concerning a 65 year old female patient with allergic reaction to AUGMENTIN and clindamycin and osteoarthritis who on 27-JAN-2009 was vaccinated with PNEUMOVAX (lot # 663012/1163X) IM. It is unknown if this is the patient's first dose of PNEUMOVAX. The patient developed a localized reaction at the site of injection. The area is large, irritated and red. The patient had visited office for medical attention. The patient's localized reaction at the injection site persisted. Follow-up information has been received from healthcare professional that the patient went to the office on 29-JAN-2009 with cellulitis-like reaction involving erythema, warmth and induration. The affected area was 4 x 6 cm on her right arm with smaller satellite lesions of erythema and induration. The healthcare professional confirmed that this had been the patient's first dose of PNEUMOVAX. A standard lot check was performed. All in-process quality checks for the lot number in question were satisfactory. In addition, an expanded lot check investigation was performed. The testing performed on the batch prior to release met all release specifications. The lot met the requirements of the Center and was released. This is the second of four patients from the same source. Additional information has been requested.
Reported to clinic for evaluation on 9/23/2021 due to concern of 6 day progressive history of BLE weakness, paresthesia, neuropathy, now with saddle anesthesia. Patient tested positive for COVID 19 on 9/13/2021 which was described as mild in course with fatigue and minimal shortness of breath.
Swelling below his armpit about 2 inches by 3 inches; Pain under his armpit; This is a spontaneous report from a contactable consumer (patient, self-reported). A 65-year-old male patient received second dose of BNT162B2 (PFIZER-BIONTEC COVID-19 mRNA VACCINE, Solution for injection, lot number and expiry date were not reported), via an unspecified route of administration, on an unspecified date, as a single dose for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. Historical vaccine included first dose of BNT162B2 (PFIZER-BIONTEC COVID-19 mRNA VACCINE, Solution for injection, lot number and expiry date were not reported), via an unspecified route of administration, on an unspecified date, as a single dose for COVID-19 immunization. The patient reported that he took his second covid vaccine dose and afterwards started having pain under his armpit. He then began having some swelling below his armpit about 2 inches by 3 inches on an unspecified date. He reported that he read that this was a side effect but asked, how long should he expect this to last. There was no rash just swelling. He had slight pain right before this developed. He has read it was a normal reaction to the second vaccine more than the first one and asked how long the swelling was expected to stay before it goes down. Caller declined to proceed with report. He has waited already one and a half hours. There was no answer online. Outcome of the events was unknown.  Information on the lot/batch number has been requested.  Follow-up attempts completed. No further information expected.
9PM on 2JUN93 fever rose to 104.4 R mom gave APAP & tepid baths until 3JUN93 in AM; t104.4 mom took to ER spinal fluid drawn; mom states fever rose to 104.8 that PM;
13th patient administered expired Moderna Covid-19 vaccine; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (13th patient administered expired Moderna Covid-19 vaccine) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 21-Sep-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 09-Sep-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (13th patient administered expired Moderna Covid-19 vaccine). At the time of the report, EXPIRED PRODUCT ADMINISTERED (13th patient administered expired Moderna Covid-19 vaccine) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No any concomitant medications were reported. No any treatment medications were reported. The patient received the vaccination on which arm was unknown. The patient had no adverse event.
Information has been received from a Registered pharmacist (R.P.) concerning a 16 year old female who on 13-APR-2010 was vaccinated with a fourth dose of GARDASIL (lot# not provided). The patient experienced a heavier than normal menses this month (May 2009). The patient sought unspecified medical attention. At the time of report the outcome was unknown. Follow up information was received from a pharmacist concerning the 15 year old female patient who on 26-AUG-2008, 29-APR-2009 and 08-JUL-2009 was vaccinated with the first, second and third doses of GARDASIL, respectively. The patient was vaccinated in left arm with the fourth dose of GARDASIL (662304/1013Y) on 13-APR-2010. It was not known what other vaccines were administered during this time frame. The patient's heavy menses this cycle were reported by her parent on 03-MAY-2010. Exact date of menses and duration were unknown. No treatment was required. At the time of the report the outcome was unknown. Additional information has been requested.
Pain at injection site,  Redness around injection site,  Headache,  Insomnia,  fatigue,
Headache, Fever, ARM PAIN; BODY ACHES SX LASTED 24 HOURS
This spontaneous report as received from a nurse on 06-NOV-2014 refers to a 78 year old male patient with chronic obstructive pulmonary disease (COPD). On an unknown date of 2009 (also reported as 5 years ago) the patient was vaccinated with ZOSTAVAX (strength, dose and lot# were unknown). Concomitant therapies included prednisone (manufacturer unknown) and LEVAQUIN. On an unknown date of 2014 (also reported as recently) the patient had a corneal transplant and had been experiencing a lot of pain in his eye. The patient had an office visit for seeking medical attention. The patient was told by his physician on 06-NOV-2014 (also reported as today) that he could possibly has ophthalmic zoster. The physician prescribed valacyclovir, but the patient stated he had not gotten the prescription filled, and may not take that medication. The outcome of events was reported as not recovered/ not resolved. Additional information has been requested.
Client received SHINGRIX dose #2 on 01/28/2019. She called to report that her first dose was fine, but that after her second dose, she had a severe "blinding" headache, nausea, fever (no documented temperature), chills, and body aches. She states that the symptoms started about 12 hours after vaccination and lasted 2-3 days. She states that she took ibuprofen and that it helped with the pain and fever. She no longer has any of these symptoms.
This spontaneous report was received from a pharmacist refers to a 65 year old female patient with no pertinent medical history or drug reaction/allergies. On 23-OCT-2014, the patient was vaccinated with a dose of PNEUMOVAX 23 (dose number not reported) lot # K007262, expiration date November 2015, 0.5 ml, intramuscular on the arm. Other suspect therapies included Influenza virus vaccine (unspecified) (dose, dose number, lot number, expiration date and route were not reported). Concomitant therapies included SYNTHROID. The pharmacist reported that a patient received a dose of PNEUMOVAX 23 and an unspecified flu shot in separate arms in the same vaccination session on 23-OCT-2014. On 24-OCT-2014 (reported as the next day) the patient called to the pharmacy to report that the PNEUMOVAX 23 injection site was "inflamed" and hot to the touch. The pharmacist reported that the patient came into the pharmacy on 25-OCT-2014 (reproted as two days after injection) and the site was red and swollen. The pharmacist suggested to the patient to used "ice and BENADRYL if tolerable, or ibuprofen to manage discomfort". At the time of the report the outcome was reported as recovering. No treatment given at the time of the report. Patient seek medical attention at the pharmacy (by phone call and at the visit). None lab test were performed. Additional information has been requested.
periorbital swelling, mild small urticaria, about 3 in arms & back;
vax given approx 3-5min later rt leg red, spotted pt screaming severely, then the other leg turned red & spotted;MD ordered cool compress + 1/2tsp DPH;pt was back to nl w/in 10min;? allerg rxn;
Vaccine associate chicken pox to neck, arms, trunk, legs.  Interestingly, symptoms started 8/27/08, so may have been an exposure from unkn. source.
Within hours after receiving vaccines developed fever 102 degrees, redness on arm, realized he had a pneumonia shot last year at private doctor, (forgot when asked at Health Department).  Saw doctor, advised to take Tylenol and cold compress.
Sore arm; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Sore arm) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Osteoarthritis. Concomitant products included DICLOFENAC for Osteoarthritis.    On 15-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 15-Apr-2021, the patient experienced PAIN IN EXTREMITY (Sore arm). At the time of the report, PAIN IN EXTREMITY (Sore arm) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       The patient was advised from her doctor to stop taking her Diclofenac for her osteoarthritis and not to take Tylenol before her vaccine. No treatment information was provided.   Most recent FOLLOW-UP information incorporated above includes: On 19-May-2021: Outcome of event updated
Immunocompromised patient received booster dose of the Moderna Covid 19 vaccine instead of a third full dose. This spontaneous case was reported by a pharmacist and describes the occurrence of ACCIDENTAL UNDERDOSE (Immunocompromised patient received booster dose of the Moderna Covid 19 vaccine instead of a third full dose.) in a 20-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Immunocompromised.   On 13-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 13-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In November 2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In November 2021, the patient experienced ACCIDENTAL UNDERDOSE (Immunocompromised patient received booster dose of the Moderna Covid 19 vaccine instead of a third full dose.). At the time of the report, ACCIDENTAL UNDERDOSE (Immunocompromised patient received booster dose of the Moderna Covid 19 vaccine instead of a third full dose.) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medication information was not provided by the reporter.                            Treatment information was not provided by the reporter. The patient wanted to know whether could receive the third dose of Moderna vaccine since was immunocompromised and how much dose will be administered, half dose or full dose.
PATIENT RECIEVED VACCINE 9:49 AM, MOVED TO POST VACCINATION AREA. BECAME DIZZY AND FAINT, WAS MOVED TO FLOOR FROM CHAIR. PASSED OUT AT 9:50 AM. CAME AROUND 9:55AM WITH NAUSEA THAT DID NOT RESULT IN VOMITTING. PATIENT SAT FOR AN ADDITIONAL 30 MINUTES WITH WIFE UNTIL FELT FINE TO LEAVE POST VACCINATION AREA AROUND 10:30AM. NO INJURY RESULTED. PATIENT ADMITTED AFTER VACCINATION THAT THIS IS A COMMON REACTION TO VACCINATION AND NEEDLES IN GENERAL.
Patient waited in pharmacy waiting area for approximately 2 hours. We checked on him numerous times and he reported being ok giving us the thumbs up. When patient left the pharmacy, a patron outside found him laying on the ground with his vaccination papers on his chest. He returned to the pharmacy. He reported feeling numbness in his arm and cloudy in his head. The NP checked his vitals and everything was within normal range excluding the BP being slightly elevated while sitting. We called EMS and he refused to go with them. He left  after the EMS visit. I conducted a follow-up call and patient reported that he felt symptomatic for 4 to 5 hours and now he doing fine.